Novo Nordisk A/S and Evotec SE: SG&A Spending Patterns Compared

A Tale of Two Companies: SG&A Spending Trends

In the world of pharmaceuticals, Novo Nordisk A/S and Evotec SE have carved distinct paths in their SG&A (Selling, General, and Administrative) expenses over the past decade. From 2014 to 2023, Novo Nordisk's SG&A expenses have surged by approximately 130%, reflecting its aggressive expansion and market penetration strategies. In contrast, Evotec SE, a smaller player, has seen its SG&A expenses grow by nearly 840%, indicating a rapid scaling of operations and investment in administrative capabilities.

Key Insights

• Novo Nordisk A/S: Starting at 26.76 billion in 2014, their SG&A expenses reached a peak of 61.60 billion by 2023, showcasing a steady growth trajectory.
• Evotec SE: With a modest beginning of 17.99 million in 2014, their expenses skyrocketed to 169.61 million in 2023, highlighting their dynamic growth strategy.

These trends underscore the contrasting growth strategies of these two pharmaceutical giants.